TY  - JOUR

T1  - Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - PharmacoEconomics

UR  - http://eprints.whiterose.ac.uk/137968/

PY  - 2018/09/24

AU  - Tappenden P

AU  - Simpson E

AU  - Hamilton J

AU  - Pollard D

AU  - Clowes M

AU  - Kaltenthaler E

AU  - Meiklejohn D

AU  - Morley N

ED  - 

DO  - DOI: 10.1007/s40273-018-0713-7

Y2  - 2024/10/19

ER  -